

Cancer Cachexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/CDA6B3E784EBEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: CDA6B3E784EBEN

Abstracts

The 7 major cancer cachexia markets are expected to exhibit a CAGR of 3.77% during 2024-2034.

The cancer cachexia market has been comprehensively analyzed in IMARC's new report titled "Cancer Cachexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer cachexia is a complex and debilitating condition that commonly occurs in individuals with cancer. It is characterized by progressive weight loss, muscle wasting, and loss of appetite, despite adequate food intake. Cachexia is more prevalent in advanced stages of cancer and can significantly impact a patient's quality of life, treatment response, and overall prognosis. While the precise mechanisms underlying cancer cachexia are not entirely comprehended, its development is influenced by various factors. These factors include the release of pro-inflammatory cytokines (small proteins involved in cell signaling), metabolic changes induced by tumors, and the body's reaction to the presence of cancer cells. The diagnosis of cancer cachexia involves a medical history and physical examination, body weight and BMI, laboratory tests, and imaging tests. The treatment involves nutritional support, appetite stimulants, physical activity, and palliative care.

The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, and non-pharmacological therapies and clinical trials is acting as

another growth-inducing factor. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms, and the benefits of using advanced treatments are creating a positive outlook for the market.

IMARC Group's new report provides an exhaustive analysis of the cancer cachexia market in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets.

According to the report, the United States has the largest patient pool for cancer cachexia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer cachexia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the cancer cachexia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the cancer cachexia market

Reimbursement scenario in the market

In-market and pipeline drugs

Cancer Cachexia - In-Market and Pipeline Drugs

This report also provides a detailed analysis of the cancer cachexia disease marketed drugs and late-stage pipeline drugs.

In-cancer cachexia Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline cancer cachexia disease Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Regulatory Status

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

How has the cancer cachexia market performed so far and how will it perform in the coming years?

What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cancer cachexia market across the seven major

markets in 2023 and what will it look like in 2034?

What is the growth rate of the cancer cachexia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cancer cachexia across the seven major markets?

What is the number of prevalent cases (2018-2034) of cancer cachexia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cancer cachexia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with cancer cachexia across the seven major markets?

What is the size of the cancer cachexia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cancer cachexia?

What will be the growth rate of patients across the seven major markets?

Cancer Cachexia: Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cancer cachexia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer cachexia market?

What are the key regulatory events related to the cancer cachexia market?

What is the structure of clinical trial landscape by status related to the cancer cachexia market?

What is the structure of clinical trial landscape by phase related to the cancer cachexia market?

market?

What is the structure of clinical trial landscape by route of administration related to the cancer cachexia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CANCER CACHEXIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CANCER CACHEXIA - DISEASES OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CANCER CACHEXIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 CANCER CACHEXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management, and Treatment
- 8.2 Treatment Algorithm

9 CANCER CACHEXIA -UNMET NEEDS

10 CANCER CACHEXIA - KEY ENDPOINTS OF TREATMENT

11 CANCER CACHEXIA -MARKETED PRODUCTS

- 11.1 List of Cancer Cachexia -Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CANCER CACHEXIA - PIPELINE PRODUCTS

12.1 List of Cancer Cachexia Pipeline Drugs Across the Top 7 Markets

12.1 Ponegromab - Pfizer

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.2 AV-380 - AVEO Pharmaceuticals

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

13 CANCER CACHEXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 CANCER CACHEXIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 CANCER CACHEXIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Cancer Cachexia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Cancer Cachexia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Cancer Cachexia - Market Size

- 15.3.1.1 Market Size (2018-2023)
- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Cancer Cachexia - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Cancer Cachexia - Access and Reimbursement Overview
- 15.4 Market Scenario – Germany
 - 15.4.1 Cancer Cachexia - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Cancer Cachexia - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Cancer Cachexia - Access and Reimbursement Overview
- 15.5 Market Scenario – France
 - 15.5.1 Cancer Cachexia - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Cancer Cachexia - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Cancer Cachexia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Cancer Cachexia - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Cancer Cachexia - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Cancer Cachexia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Cancer Cachexia - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Cancer Cachexia - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Cancer Cachexia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain

- 15.8.1 Cancer Cachexia - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Cancer Cachexia - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Cancer Cachexia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Cancer Cachexia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Cancer Cachexia - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Cancer Cachexia - Access and Reimbursement Overview

16 CANCER CACHEXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CANCER CACHEXIA - MARKET- SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CANCER CACHEXIA – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Cancer Cachexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/CDA6B3E784EBEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDA6B3E784EBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

